Nuwellis Files to Sell 4.28M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy NUWE?
Nuwellis files to sell 4.28M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUWE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUWE
Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 2.470
Low
3.90
Averages
3.90
High
3.90
Current: 2.470
Low
3.90
Averages
3.90
High
3.90
About NUWE
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Decline After Trump's Fed Chair Nomination
- Increased Market Volatility: Trump's nomination of former Fed official Warsh as the new Fed chair unsettled investors, leading to significant declines in major indices as market participants reacted to heightened uncertainty regarding future monetary policy.
- Gold and Silver Plunge: Following Warsh's nomination, gold and silver experienced their steepest declines in decades, prompting investors to reassess monetary policy risks and resulting in a substantial loss of confidence among precious metal investors.
- Corporate Earnings Impact: Microsoft saw its shares drop sharply despite reporting better-than-expected earnings, as concerns over slowing Azure growth and cautious guidance weighed heavily on investor sentiment, contrasting with Meta's stock rally driven by strong advertising and engagement metrics.
- Rising Treasury Yields: As expectations for a more hawkish Fed stance grew, Treasury yields edged higher while equities retreated, and commodities lost significant recent gains, reflecting a cautious outlook among investors regarding the economic landscape ahead.
See More
Nuwellis Appoints New CFO, Shares Drop 16.47%
- Executive Change: Nuwellis announced the appointment of Carisa Schultz as CFO, effective February 2, 2026, indicating a strategic shift in financial management that could impact future financial decisions and investor confidence.
- Stock Price Volatility: Following the announcement, Nuwellis shares dropped 16.47% in pre-market trading to $3.50, reflecting market uncertainty regarding the new CFO and potential implications for the company's future financial performance.
- Financial Background: Schultz most recently served as vice president of finance at NeueHealth, bringing extensive financial management experience that is expected to provide Nuwellis with new financial perspectives and strategic direction to enhance performance in the competitive healthcare sector.
- Performance Overview: Nuwellis' recent Q3 2025 earnings report showed a GAAP EPS of $0.56 and revenue of $2.22 million, and while the performance is decent, the executive change may negatively affect investor confidence and future earnings expectations.
See More
Nuwellis Acquires Israeli MedTech Firm Rendiatech
- Acquisition Agreement: Nuwellis announced a definitive agreement to acquire Israeli MedTech firm Rendiatech, aimed at expanding its cardiorenal portfolio, which is expected to enhance its product offerings in critical care settings.
- Technology Integration: The acquisition will incorporate Rendiatech's Clarity system, which provides continuous automated urine output monitoring, thereby improving Nuwellis' monitoring capabilities in critical care environments and enhancing patient care quality.
- Financing Details: Nuwellis raised approximately $5 million through a private placement and warrant inducement transaction priced at-the-market under Nasdaq rules, with the closing expected around January 30, which will further bolster the company's liquidity.
- Market Reaction: Following the acquisition announcement, Nuwellis' stock fell 15.27% in after-hours trading to $3.55, reflecting market caution regarding the acquisition and financing activities.
See More
Nuwellis Inc. Shares Plunge 26% After Rendiatech Acquisition Announcement
- Acquisition Agreement: Nuwellis Inc. has announced an agreement to acquire Israeli medical technology firm Rendiatech, aiming to expand its portfolio into real-time renal diagnostics, although the deal's value remains undisclosed, which may impact the company's future market competitiveness.
- Stock Reaction: Following the acquisition announcement, Nuwellis Inc.'s shares plummeted over 26% in after-hours trading, reflecting market concerns regarding the acquisition and its potential implications for the company's financial health.
- Funding Plan: The company also announced a $5 million private placement and warrant inducement transaction, aimed at providing financial support for the acquisition; despite the negative market reaction, this move could help strengthen the company's capital structure.
- Technology Integration: With Rendiatech focusing on automated kidney function monitoring, the acquisition may accelerate Nuwellis's technology integration in the renal health sector, enhancing its product competitiveness and innovation capabilities.
See More
Nuwellis Inc Shares Surge Over 100% Amid Board Restructuring and Patent News
- Stock Surge: Nuwellis Inc's stock skyrocketed over 100% in pre-market trading on Tuesday, maintaining an approximately 85% increase by 10 AM ET, indicating strong investor interest in this nearly $2 million microcap medical device maker.
- Board Restructuring: Last week, Nuwellis disclosed a significant board shakeup with three long-serving directors stepping down and two new directors with experience in scaling medical technology companies joining, suggesting preparations for faster execution and strategic initiatives.
- Patent Advantage: The company secured a new patent for its Vivian™ Pediatric CRRT System in January, bolstering its intellectual property in the niche but high-margin infant blood filtration market, which could attract acquisition interest from larger players despite its small size.
- Market Attention: With a razor-thin float and limited liquidity, Nuwellis's stock surge reflects retail traders chasing the narrative around its patents and board changes, as the market begins to recognize the potential value of this microcap in the infant healthcare sector.
See More
General Motors Reports Strong Q4 Earnings and Dividend Increase
- Earnings Beat: General Motors reported fourth-quarter adjusted earnings per share of $2.51, a 30.4% year-over-year increase that surpassed analyst expectations of $2.20, indicating a significant improvement in profitability.
- Sales Miss: The company's quarterly sales reached $45.287 billion, falling short of the market expectation of $45.804 billion, reflecting challenges from increased market competition and demand fluctuations.
- Dividend Increase: The Board of Directors approved a 3-cent increase in the quarterly common stock dividend to 18 cents per share, demonstrating confidence in future cash flows and commitment to shareholder returns.
- Share Repurchase Program: GM announced a new $6 billion share repurchase authorization aimed at enhancing earnings per share by reducing the number of shares outstanding, thereby boosting investor confidence.
See More
US Stocks Decline After Trump's Fed Chair Nomination
- Increased Market Volatility: Trump's nomination of former Fed official Warsh as the new Fed chair unsettled investors, leading to significant declines in major indices as market participants reacted to heightened uncertainty regarding future monetary policy.
- Gold and Silver Plunge: Following Warsh's nomination, gold and silver experienced their steepest declines in decades, prompting investors to reassess monetary policy risks and resulting in a substantial loss of confidence among precious metal investors.
- Corporate Earnings Impact: Microsoft saw its shares drop sharply despite reporting better-than-expected earnings, as concerns over slowing Azure growth and cautious guidance weighed heavily on investor sentiment, contrasting with Meta's stock rally driven by strong advertising and engagement metrics.
- Rising Treasury Yields: As expectations for a more hawkish Fed stance grew, Treasury yields edged higher while equities retreated, and commodities lost significant recent gains, reflecting a cautious outlook among investors regarding the economic landscape ahead.
See More
Nuwellis Appoints New CFO, Shares Drop 16.47%
- Executive Change: Nuwellis announced the appointment of Carisa Schultz as CFO, effective February 2, 2026, indicating a strategic shift in financial management that could impact future financial decisions and investor confidence.
- Stock Price Volatility: Following the announcement, Nuwellis shares dropped 16.47% in pre-market trading to $3.50, reflecting market uncertainty regarding the new CFO and potential implications for the company's future financial performance.
- Financial Background: Schultz most recently served as vice president of finance at NeueHealth, bringing extensive financial management experience that is expected to provide Nuwellis with new financial perspectives and strategic direction to enhance performance in the competitive healthcare sector.
- Performance Overview: Nuwellis' recent Q3 2025 earnings report showed a GAAP EPS of $0.56 and revenue of $2.22 million, and while the performance is decent, the executive change may negatively affect investor confidence and future earnings expectations.
See More
Nuwellis Acquires Israeli MedTech Firm Rendiatech
- Acquisition Agreement: Nuwellis announced a definitive agreement to acquire Israeli MedTech firm Rendiatech, aimed at expanding its cardiorenal portfolio, which is expected to enhance its product offerings in critical care settings.
- Technology Integration: The acquisition will incorporate Rendiatech's Clarity system, which provides continuous automated urine output monitoring, thereby improving Nuwellis' monitoring capabilities in critical care environments and enhancing patient care quality.
- Financing Details: Nuwellis raised approximately $5 million through a private placement and warrant inducement transaction priced at-the-market under Nasdaq rules, with the closing expected around January 30, which will further bolster the company's liquidity.
- Market Reaction: Following the acquisition announcement, Nuwellis' stock fell 15.27% in after-hours trading to $3.55, reflecting market caution regarding the acquisition and financing activities.
See More
Nuwellis Inc. Shares Plunge 26% After Rendiatech Acquisition Announcement
- Acquisition Agreement: Nuwellis Inc. has announced an agreement to acquire Israeli medical technology firm Rendiatech, aiming to expand its portfolio into real-time renal diagnostics, although the deal's value remains undisclosed, which may impact the company's future market competitiveness.
- Stock Reaction: Following the acquisition announcement, Nuwellis Inc.'s shares plummeted over 26% in after-hours trading, reflecting market concerns regarding the acquisition and its potential implications for the company's financial health.
- Funding Plan: The company also announced a $5 million private placement and warrant inducement transaction, aimed at providing financial support for the acquisition; despite the negative market reaction, this move could help strengthen the company's capital structure.
- Technology Integration: With Rendiatech focusing on automated kidney function monitoring, the acquisition may accelerate Nuwellis's technology integration in the renal health sector, enhancing its product competitiveness and innovation capabilities.
See More
Nuwellis Inc Shares Surge Over 100% Amid Board Restructuring and Patent News
- Stock Surge: Nuwellis Inc's stock skyrocketed over 100% in pre-market trading on Tuesday, maintaining an approximately 85% increase by 10 AM ET, indicating strong investor interest in this nearly $2 million microcap medical device maker.
- Board Restructuring: Last week, Nuwellis disclosed a significant board shakeup with three long-serving directors stepping down and two new directors with experience in scaling medical technology companies joining, suggesting preparations for faster execution and strategic initiatives.
- Patent Advantage: The company secured a new patent for its Vivian™ Pediatric CRRT System in January, bolstering its intellectual property in the niche but high-margin infant blood filtration market, which could attract acquisition interest from larger players despite its small size.
- Market Attention: With a razor-thin float and limited liquidity, Nuwellis's stock surge reflects retail traders chasing the narrative around its patents and board changes, as the market begins to recognize the potential value of this microcap in the infant healthcare sector.
See More
General Motors Reports Strong Q4 Earnings and Dividend Increase
- Earnings Beat: General Motors reported fourth-quarter adjusted earnings per share of $2.51, a 30.4% year-over-year increase that surpassed analyst expectations of $2.20, indicating a significant improvement in profitability.
- Sales Miss: The company's quarterly sales reached $45.287 billion, falling short of the market expectation of $45.804 billion, reflecting challenges from increased market competition and demand fluctuations.
- Dividend Increase: The Board of Directors approved a 3-cent increase in the quarterly common stock dividend to 18 cents per share, demonstrating confidence in future cash flows and commitment to shareholder returns.
- Share Repurchase Program: GM announced a new $6 billion share repurchase authorization aimed at enhancing earnings per share by reducing the number of shares outstanding, thereby boosting investor confidence.
See More
